4.1 Article

Catastrophic Antiphospholipid Syndrome and Renal Failure: An Unexpected Recovery After Three Years on Dialysis

Journal

CUREUS JOURNAL OF MEDICAL SCIENCE
Volume 15, Issue 5, Pages -

Publisher

SPRINGERNATURE
DOI: 10.7759/cureus.38851

Keywords

anticoagulation; renal failure; primary antiphospholipid syndrome; catastrophic antiphospholipid syndrome; autoimmune disease

Ask authors/readers for more resources

Catastrophic antiphospholipid syndrome is a rare and life-threatening disorder characterized by multiple thrombotic events involving three or more organs in a short period of time, in the presence of persistent antiphospholipid antibodies. The optimal management of CAPS is unclear with a lack of consensus among experts. We report a case of a patient with primary antiphospholipid syndrome who experienced probable CAPS after receiving rivaroxaban, resulting in extensive cutaneous ulceration, acute coronary syndrome, and dialysis-dependent renal failure. Treatment with anticoagulation, glucocorticoids, and plasmapheresis, along with long-term vitamin K antagonist, resulted in the healing of skin lesions, regression of cardiac lesions, and recovery of renal function after three years on dialysis.
Catastrophic antiphospholipid syndrome (CAPS) is a rare and life-threatening disorder characterised by arterial or venous thrombotic events, involving three or more organs in a short period of time, in the presence of persistent antiphospholipid antibodies. Long-term anticoagulation with warfarin is the standard of care to prevent recurrent vascular events. Besides supportive care, optimal management of CAPS is unclear and consensus among experts is lacking. We describe a patient with primary antiphospholipid syndrome who experienced probable CAPS after receiving rivaroxaban, resulting in extensive cutaneous ulceration, acute coronary syndrome and dialysis-dependent renal failure. Anticoagulation, glucocorticoids and plasmapheresis were started. In the haemodialysis period, he maintained treatment with long-term vitamin K antagonist. The international normalized ratio target was optimized to 3.5-4. This strategy was associated with the healing of skin lesions, regression of cardiac lesions and recovery of renal function after three years on dialysis.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.1
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available